
|Videos|May 30, 2017
Differentiating Factors of Abemaciclib Among the CDK 4/6 Inhibitors for Breast Cancer
Author(s)Hope S. Rugo, MD
Hope S. Rugo, MD, discusses the differentiating factors of abemaciclib among the CDK 4/6 inhibitors for breast cancer treatment.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































